Vmbook Online ordering
Biotechnology
Sure, I'm happy to help. The public company Biotechnology with the stock symbol CSBR is likely Catalyst Biosciences, Inc.
According to Yahoo finance, Catalyst Biosciences, Inc. is a biopharmaceutical company that focuses on creating new drugs that target host cell proteins to prevent or treat diseases. The company's product candidate includes marzeptacog alfa, which is in Phase III clinical trials for the treatment of hemophilia A; and CB 2679d, which is in Phase II clinical trials for the treatment of bleeding disorders.
In terms of financials, here are some key points:
* Market Cap: 368.32M
* Industry: Biotechnology
* Sector: Healthcare
* Fiscal Year-End: December
Earnings:
* The company's earnings history can be found on Yahoo Finance. The most recent earnings report was released on November 10, 2022, for the third quarter ending September 30, 2022. The company reported a net loss of $22.9 million, or ($0.63) per share, compared to a net loss of $23.4 million, or ($0.72) per share, for the same period in the previous year.
* Revenue for the quarter was $1.1 million, up from $0.3 million for the same period in the previous year.
* Analysts estimate that the company will report earnings per share of ($0.62) for the current quarter.
Growth:
* Catalyst Biosciences, Inc. has seen significant growth in recent years, primarily due to its acquisition of Pharsight Corporation in 2017. The acquisition expanded the company's product portfolio and provided opportunities for further growth.
* In terms of revenue growth, the company has seen a compound annual growth rate of 25.60% over the past five years.
* The company's revenue growth has been primarily driven by the commercial success of its drugs, as well as its partnerships with other pharmaceutical companies.
Nearly 27 institutional investors increased their position in Catalyst Biosciences, Inc. by around 25% over the previous quarter. Some of these institutional investors include BlackRock Inc., Vanguard Group Inc., and NEA Management Company LLC.
In summary, Catalyst Biosciences, Inc. is a biotechnology company focused on developing novel treatments for bleeding disorders and other diseases. The company has seen significant revenue growth in recent years, primarily driven by its commercial success and partnerships with other pharmaceutical companies. In terms of earnings, the company has reported a net loss in its most recent quarter, but analysts estimate that the company will report negative earnings per share for the current quarter. Nearly 27 institutional investors have increased their positions in the company over the previous quarter. Catalyst Biosciences, Inc. represents a promising investment opportunity for investors seeking exposure to the biotechnology sector.
I hope this was helpful! Let me know if you have any other questions.